argenx Presents New VYVGART Data at AANEM and MGFA, Showing Earlier and Sustained Treatment Outcomes in MG and CIDP
argenx presented new data from across its portfolio at the 2026 AANEM Annual Meeting and the MGFA Scientific Session in Orlando, with results supporting earlier and sustained treatment with VYVGART in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP).
Highlights include one-year ADAPT SERON results showing sustained efficacy in patients with generalized MG who do not have detectable anti-AChR antibodies, with improvements of approximately 5 points on the MG-ADL scale maintained through Week 52, and a post hoc analysis in CIDP in which VYVGART Hytrulo reduced the relative risk of grip strength deterioration by 71.5%. The company also shared updates across its neuromuscular pipeline, including empasiprubart and adimanebart.
